COMMUNIQUÉS West-GlobeNewswire

Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
06/10/2026
Preclinical data highlighting ERNA-101’s potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer Center in Houston [...]
Confluent Health Names Tony Kaczkowski CEO of Industrial Health & Safety Solutions Division
06/10/2026
LOUISVILLE, Ky. -- Oct. 6, 2026, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Confluent Health , a national leader in musculoskeletal (MSK) care, today announced that Tony Kaczkowski has been named Chief Executive Officer (CEO) of [...]
RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
06/10/2026
Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures. Financing will [...]
Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program
06/10/2026
Financing will be used to advance Rewind's lead oral program designed to promote remyelination and restore neurological function Peer-reviewed data published in PLOS ONE demonstrated remyelination and functional [...]
RQ Bio Appoints Gavin Koh as Chief Medical Officer and Strengthens Leadership to Advance RQB01
06/10/2026
Dr Koh brings extensive infectious disease and clinical development expertise as RQ Bio prepares to advance RQB01 into the clinic Senior appointments across CMC, clinical operations and programme management further [...]
Angelini Ventures and EIB Co-lead $58 Million Series A Financing in Rouge Therapeutics to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
06/10/2026
Marks the fourth investment completed under Angelini Ventures’ €150 million co-investment partnership with the European Investment Bank in less than 12 months Regina Hodits from Angelini Ventures to join Rouge [...]
Resolution Therapeutics to present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026
06/10/2026
Interim data from Phase I/II EMERALD study for RTX001, Resolution’s engineered Regenerative Macrophage Therapy, accepted as late-breaking presentation Dr. Lara Campana to present preclinical data on intravenous [...]
Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
06/10/2026
Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización en Europa. El [...]
Transactions in connection with share buy-back program
06/10/2026
Company announcement no. 38 - 26 06 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.
06/10/2026
Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l’innovativo impianto per la riparazione della cartilagine. La tecnologia sarà presentata [...]
Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
06/10/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CARTIHEAL Implant will [...]
Peptides Canada Operated by Growth Guys Announces Launch of Domestic Research Peptide Supply Platform
06/10/2026
TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Peptides Canada , operated by Growth Guys, today announced the launch of its Canadian research-peptide supply platform , providing a domestic online source for peptide [...]
Nox Peptides Announces Expanded Research Focus on BPC-157 as Canadian Peptide Research Supply Demand Grows
06/10/2026
Toronto, ON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nox Peptides today announced an expanded focus on providing information and access to research peptide supplies for Canadian laboratories, academic researchers and [...]
Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire »
06/10/2026
Mise en ligne du document «Q3 2026 aide-mémoire » Paris, France – 6 octobre 2026 . Sanofi annonce la mise en ligne de son « Q3 2026 aide-mémoire » sur la page « Investisseurs » de sanofi.com. Résultats du troisième [...]
Press Release : Availability of the aide-mémoire for Q3 2026 results
06/10/2026
Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026 . Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter [...]
Kylo Peptides Review Brings Transparency to the Research Peptide Market
06/10/2026
Review highlights testing documentation, lot-specific COAs, independent laboratory analysis, and supplier information to help researchers evaluate research peptide sources. Sheridan, Wyoming, Oct. 06, 2026 (GLOBE [...]
Bulk Peptides: Kylo Peptides Launches Bulk Research Program for High-Volume Laboratories
06/10/2026
Sheridan, Wyoming, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ] has introduced a research program that supplies bulk peptides to laboratories with higher-volume peptide requirements. It [...]
Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market
06/10/2026
ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market Orion Corporation (“Orion Pharma”) and Qilu Pharma [...]
One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event
06/10/2026
First clinical data for CPV-104 in patients, including interim safety, tolerability and pharmacokinetics, accepted as a late-breaking poster Expert panel to join One04 management in a virtual key opinion leader (KOL) [...]

Pages